About Stealth Peptides

Stealth Peptides (Stealth) is a privately held, clinical stage, biopharmaceutical company developing novel and innovative mitochondrial targeted therapies for diseases with clear unmet medical needs including cardiovascular, renal, ophthalmologic, neurologic and metabolic conditions.

Stealth’s first clinical candidate is Bendavia™, a new chemical entity (NCE) that targets the mitochondria. Preclinical studies have shown this compound’s ability to reduce the amount of ischemia reperfusion injury (IR) in a variety of animal models. Stealth’s initial clinical development program targets acute myocardial infarction (AMI), an indication with well defined and clear clinical metrics. This allows a rapid demonstration of well defined measures of biologic activity in a target population and provides a clear pathway forward for regulatory approval.

Stealth operates as a streamlined company that efficiently integrates deeply experienced consultants and advisors with its core team.